SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Survival of human carrier erythrocytes in vivo

Bax, BE; Bain, MD; Talbot, PJ; Parker-Williams, EJ; Chalmers, RA (1999) Survival of human carrier erythrocytes in vivo. CLINICAL SCIENCE, 96 (2). 171 - 178. ISSN 0143-5221 https://doi.org/10.1042/CS19980229
SGUL Authors: Bax, Bridget Elizabeth

[img] ["document_typename_cannot open `/data/SGUL/sgul/eprints3/archives/sgul/documents/disk0/00/10/04/49/09/In' (No such file or directory) cannot open `Vivo' (No such file or directory) cannot open `Survival' (No such file or directory) cannot open `text.doc' (No such file or di" not defined] Accepted Version
Download (52kB)

Abstract

Erythrocytes offer the exciting opportunity of being used as carriers of therapeutic agents. Encapsulation within erythrocytes will give the therapeutic agent a clearance equivalent to the normal life of the erythrocyte therefore maintaining therapeutic blood levels over prolonged periods and also giving a sustained delivery to the monocyte–macrophage system (reticulo-endothelial system). Both the dose and frequency of therapeutic interventions could thus be reduced. Ensuring a near-physiological survival time of carrier erythrocytes is essential to their successful use as a sustained drug delivery system, and this has not been demonstrated in man. In this study we assessed the survival in vivo of autologous unloaded energy-replete carrier erythrocytes in nine volunteers, using a standard 51Cr erythrocyte-labelling technique. Within 144 h after infusion there was a 3 to 49% fall in circulating labelled cells, followed thereafter by an almost complete return to initial circulating levels; surface counting demonstrated an initial sequestration of erythrocytes by the spleen and subsequent release. Mean cell life and cell half-life of the carrier erythrocytes were within the normal range of 89 to 131 days and 19 to 29 days respectively. These results demonstrate the viability of carrier erythrocytes as a sustained drug delivery system.

Item Type: Article
Additional Information: The final version of this article is available at Clincal Science. http://dx.doi.org/10.1042/CS19980229
Keywords: Adult, Chromium Radioisotopes, Dialysis, Drug Carriers, Erythrocyte Aging, Erythrocyte Count, Female, Heart, Humans, Lung, Male, Spleen, Time Factors, Science & Technology, Life Sciences & Biomedicine, Medicine, Research & Experimental, Research & Experimental Medicine, chromium radioisotopes, drug delivery systems, erythrocyte, erythrocyte ageing, erythrocyte membrane, RED-BLOOD-CELLS, INOSITOL-HEXAPHOSPHATE, ENTRAPMENT
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: CLINICAL SCIENCE
ISSN: 0143-5221
Related URLs:
Dates:
DateEvent
1 February 1999Published
Web of Science ID: WOS:000078706000007
URI: https://openaccess.sgul.ac.uk/id/eprint/100449
Publisher's version: https://doi.org/10.1042/CS19980229

Statistics

Item downloaded times since 30 Sep 2014.

Actions (login required)

Edit Item Edit Item